SCHEMBL5023191

SCHEMBL5023191

CC(C)CNC(=O)c1cc2cc(OC3CCN(C(C)C)C3)ccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 13/20 0.59
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
NAMPT P43490 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379101 0.94 HRH3 (0.66) HRH3KDM4E
SCHEMBL5017142 0.87 HRH3 (0.60) HRH3KDM4EALDH1A1MAPT
SCHEMBL5023289 0.85 HRH3 (0.66) HRH3
SCHEMBL5023593 0.85 HRH3 (0.66) HRH3
SCHEMBL5023212 0.84 HRH3 (0.64) HRH3
SCHEMBL5023213 0.83 HRH3 (0.65) HRH3
SCHEMBL5016961 0.83 HRH3 (0.65) HRH3KDM4EALDH1A1MAPT
SCHEMBL5023575 0.83 HRH3 (0.64) HRH3KDM4E
SCHEMBL1552632 0.82 HRH3 (0.61) HRH3KDM4EALDH1A1MAPT
SCHEMBL1552813 0.82 HRH3 (0.61) HRH3KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761519-B1 INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-05-07 EP disclosed
US-7361682-B2 Indole derivatives as H3 inverse agonists HOFFMANN-LA ROCHE INC. (US) 2008-04-22 US disclosed
EP-1761519-A1 INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP disclosed
WO-2005123716-A1 INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO disclosed
US-20050282864-A1 Indole derivatives as H3 inverse agonists HOFFMANN-LA ROCHE INC. 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282864-A1 Indole derivatives as H3 inverse agonists HRH3, HRH4, ADRB1 HRH3 1/4885KDM4E 1001/4885ALDH1A1 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.